U.S.-based clinical trial shows mortality rate for COVID-19 patients fell 40% with Ivermectin.
Dose: “at least one oral dose of ivermectin at 200 micrograms/kilogram”
Reprinted for educational purposes and social benefit, not for profit.
Abstract Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective: To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting: Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants: 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure: Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures: The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results: Univariate analysis showed lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance: Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials.
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro – Science Direct
- Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
- A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.
- Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
- Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
- ABSTRACT. Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
- DOWNLOAD PDF
- African Programme for Onchocerciasis Control (APOC) with Ivermectin – WHO
- IVOMEC® (ivermectin) – Boehringer Ingelheim
- MECTIZAN® (ivermectin) – Merck
- STROMECTOL® (Ivermectin) – Merck
- What are the generic sources for ivermectin and what is the scope of patent protection?
- Ivermectin is the generic ingredient in four branded drugs marketed by Perrigo Uk Finco, Teva Pharms Usa, Galderma Labs Lp, Taro, Arbor Pharms Llc, Edenbridge Pharms, and Merck Sharp Dohme, and is included in seven NDAs. There are thirteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
- Ivermectin has ninety-eight patent family members in twenty-nine countries.
- There are five drug master file entries for ivermectin. Seven suppliers are listed for this compound. There is one tentative approval for this compound.
The Florida report was apparently the standard recommended FDA approved dosage: “at least one oral dose of ivermectin at 200 micrograms/kilogram”
If there is no selection bias, this is a real breakthrough.
23 clinical trials in the works: Argentina, Egypt, Iraq, United States, Israel, Mexico, Spain, Argentina, Egypt, Pakistan, Egypt, Egypt, India, Egypt, Mexico, United States, Argentina, Egypt
- New clinical trial to investigate the efficacy of ivermectin against COVID-19 – May 14
- US Trial Finds Drug Cuts Coronavirus Mortality 40% – June 11
- Preliminary findings released Tuesday for a U.S.-based clinical trial of anti-parasite drug ivermectin found that the mortality rate for coronavirus patients fell 40%, according to the Medrxiv.org site. The ivermectin study — it began in March as part of a larger Australian-led clinical study — focused on 280 patients, 173 of whom were treated with the drug at four Broward County, Florida, hospitals. The research team was led by Dr. Jean-Jacques Rajter, a Broward Health Medical Center physician, and his wife, Juliana Cepelowicz Rajter. The findings reported in Medrxiv, “ICON (Ivermectin in COVID-19) Study: Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With COVID-19,” said that patients who took part in the trial were given a single dose of the anti-parasitic medication, and some received a second dose a week later. The dose given the COVID-19 patients was the same as the FDA-approved dose used to treat patients with intestinal parasites. According to Medrxiv.org, the Broward study found that overall mortality among seriously ill COVID-19 patients treated with the drug was 15%. Mortality among patients in a similar disease state who did not receive ivermectin was 25%. That would equate to a 40% drop in mortality, a statistically significant difference. “It’s amazing and could literally pull people back from critical COVID-19 illness,” according to board certified emergency medicine physician Dr. Peter Hibberd, M.D. In an interview Tuesday, Hibberd hailed the results as a “major breakthrough in COVID-19 management.” If reviewed successfully, Ivermectin could become the first COVID-19 therapy shown to reduce mortality risk in seriously ill patients in a clinical trial. A previous therapeutic medication, remdesivir, has already won FDA emergency use authorization. Trials showed remdesivir shortened patients’ hospital stays, but did not show a statistically significant improvement in reducing overall mortality, according to the National Institutes of Health. “Even if it was judged to need a second dose in seven days,” Hibberd said, “it remains a breakthrough in COVID-19 management.” Medical experts aren’t sure yet precisely how the drug counters COVID-19. Some suspect it could be blocking a protein that the virus requires in order to reproduce. Perhaps the study’s most impressive finding: The effect the drug had on 75 sick COVID-19 patients who were suffering from “severe pulmonary disease” – a very high-risk group. Of patients in that group who did not receive ivermectin, 81% died. Yet the mortality rate for patients with severe pulmonary disease who did receive ivermectin was 39 percent. In other words, for the most severely ill patients with severe pulmonary disease, the use of ivermectin improved the odds of survival by just over 50%. As news of ivermectin — which is used globally to treat scabies, lice and other parasitic diseases — has spread on the internet, the FDA has warned patients against trying to treat themselves with it. The FDA on May 1 posted the following advisory: “While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19.” Ivermectin is generally considered safe, however, the FDA warned consumers to never use any form of the drug intended for use by animals. Hibberd said that once the study is peer-reviewed, he would like to see the FDA grant emergency-use authorization for ivermectin as a coronavirus treatment – to be used under expert medical supervision — as soon as possible. When used as prescribed, he said, ivermectin has a very strong safety record. “This drug has been used for over 30 years by millions of people around the world, and has a marked safety base,” he told Newsmax. “We understand fully its side effects, and the effect of a single dose in such a critically diseased state cannot be ignored.” Hibberd tells Newsmax that several major U.S. medical centers already list ivermectin as a COVID-19 treatment. It is also reportedly being used to fight the virus in Bolivia, Peru, India, and other nations. Over a dozen clinical trials of the drug are also reportedly underway in Egypt, Iraq, Argentina, Brazil, Mexico and Australia. Ivermectin first emerged as a possible coronavirus therapeutic when a study by researchers from Royal Melbourne University and Monash University in Victoria, Australia showed the drug wiped out the virus in a test tube. Noting patients who received the drug in the Broward County study were already quite ill, Hibberd suggested that giving ivermectin to patients earlier in the disease cycle could be even more beneficial, and might even help them avoid hospitalization altogether. “That’s why the results were so surprising,” he told Newsmax, “because these people already had damage in their lungs with a rapidly downhill progression.” “Some of these patients were in extreme distress and rapidly going downhill,” he added, “and their clinical course stabilized with 24 to 48 hours.” Some patients went home three to four days after receiving treatment, he said.